Document is current
Any future updates will be listed below
-
Authors
Brillac, Claire https://orcid.org/0000-0002-1743-3211
Sémiond, Dorothée
Oprea, Corina
Baruchel, André https://orcid.org/0000-0003-0120-6089
Zwaan, C. Michel https://orcid.org/0000-0001-6892-8268
Nguyen, Laurent
-
Funding
Funding for this research was provided by:
Sanofi
- License Information
-
More Information
Article History
Received: 6 July 2025
Accepted: 16 October 2025
First Online: 3 December 2025
Declarations
:
: CB, CO, DS, and LN: Employees of Sanofi and may hold shares and/or stock options in the company. AB: Advisory role – Amgen, AstraZeneca, Novartis, Sanofi, and Servier; Research funding – Servier and Shire; Investigator – Bristol Myers Squibb, Cellectis, Kite/Gilead Sciences, Sanofi, and Wugen. CMZ: Support for the present manuscript – Sanofi; Consulting – Janssen and Sanofi; Data Safety Monitoring or Advisory role – Novartis and Sanofi; Leadership role – Innovative Therapies for Children with Cancer Hematology Committee; Funding for clinical trials – AbbVie, Bristol Myers Squibb, Daiichi Sankyo, Jazz, Kura Oncology, Pfizer, and Takeda.
: Both ISAKIDS and ISLAY were conducted according to the Declaration of Helsinki and the International Conference on Harmonization Good Clinical Practice Guidelines. The protocol was approved by institutional review boards and independent ethics committees at all participating institutions. Informed consent was obtained for each participant according to local regulations. The funder of the study, Sanofi, had roles in study design, data collection, data analysis, data interpretation, and writing of the report.
